InRoseLab is VenusRoses Labsolutions new product line
PainBlock Joints
Capsules
PainBlock Joints is an advanced joint support formula designed for adults 40+ experiencing joint pain, stiffness, and reduced mobility in knees, hands, and fingers.
Powered by clinically studied Levagen+® (PEA) with precision microfluidic delivery for enhanced absorption and targeted action.
CLINICALLY
STUDIED
INGREDIENTS
INNOVATIVE ENCAPSULATION TECHNOLOGY
QUALITY CERTIFICATES
MADE IN EUROPEAN
UNION
Up to 40–50%
of adults
report occasional joint pain, stiffness, or discomfort.
Symptoms most commonly affect the knees, hands, and fingers.
Source: Centers for Disease Control and Prevention – Arthritis prevalence and burden data (CDC Arthritis Program)
After the age of 40, joint discomfort becomes increasingly common.
Pain, stiffness, and reduced mobility in the knees, hands, and fingers affect a significant portion of active adults and can limit everyday activities.
With age, the risk of conditions such as osteoarthritis increases, making joint care essential for maintaining movement, comfort, and quality of life.
Source: World Health Organization – Osteoarthritis fact sheet
WHY TO
CHOOSE
PainBlock Joints
Capsules
1
CLINICALLY
STUDIED
INGREDIENTS
2
INNOVATIVE ENCAPSULATION
TECHNOLOGY
3
QUALITY
CERTIFICATES
CLINICALLY STUDIED
INGREDIENTS
Levagen+®
ROSA
DAMASCENE
OIL (flowers)
ROSA DAMASCENE OIL
The rose oil contains more than 345 macro and micro components.
Rose Oil frequency is extremely high and rapid.
Rose oil has the highest frequency (320 Hertz) of all the essential oils on the planet. This in itself is an important factor.
Clinical research shows that Rose essential oils have the highest frequency of any natural substance known to man, creating an environment in which disease, bacteria, virus, fungus, etc., cannot live.
Studies: Rose oils are complex and 95 compounds were identified (94.75% of the oil), monoterpene alcohols: beta-citronellol 26%;
From: Medical Herbs, 2011
Rosa Damascene Oil has strong antioxidant and anti-inflammatory properties.
Inflammation is one of the mechanisms associated with joint discomfort and reduced mobility.
LEVAGEN®+
Scientifically Validated to Reset the Chronic Pain.
What is Levagen®+ Palmitoylethanolamide (PEA)?
Levagen+ has important anti-inflammatory, analgesic and neuro-protective properties
Joint pain affects various individuals, whether an active senior or elite athlete, which leads to decreased quality of life, reduced performance and immobility.
Levagen® has been proven to improve symptoms of joint discomfort, stiffness and function dose-dependently over the course of 8 weeks.
Palmitoylethanolamide is both a powerful anti-inflammatory and pain reliever, providing an all-in-one solution for managing discomfort.
Why do we need it?
Levels of PEA naturally decreases in the body in response to a pro-inflammatory stimulus (e.g. age, exercise-induced inflammation and/or stress).
Therefore, supplementation is needed to restore normal levels of this endogenous compound.
*Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants-A Double-Blind Randomised Controlled Study
David Briskey 1 2 , Rachael Skinner 1 , Chelsie Smith 1 , Amanda Rao 1 2
Levagen®+ is a registered trademark of Gencor Pacific Ltd.
LipiSperse® is a patented technology and trademark owned exclusively by Pharmako Biotechnologies Pty
-
A commonality of all joint pain is the existence of inflammation. Palmitoylethanolamide (PEA) is an endogenous saturated fatty acid derivative that down-regulates multiple proinflammatory and nociceptive pathways and is known to inhibit mast and glial cell activity.
This study aimed to assess the efficacy of PEA (Levagen+) for alleviating joint pain and improving quality of life in adults. A randomized, double-blind, placebo-controlled study was conducted on adults reporting joint pain.
Seventy-four participants received either PEA (n=35) or a placebo (n=39) daily for 2 weeks and completed the study. The primary outcome was a self-assessed reduction in pain, measured using a visual analogue scale (VAS) for pain, completed in the morning and evening.
VAS pain scores decreased over the 2-week treatment period in both groups. Morning VAS scores were significantly reduced from baseline in the PEA and placebo groups from day 3 and day 4 respectively.
VAS scores were significantly lower in the PEA group compared to the placebo group on day 14 (P<0.05). Evening VAS scores were significantly reduced from baseline in both the PEA and placebo groups from day 3.
Total mood scores for both groups were similar at baseline but differed significantly at the end of the study, with scores decreasing in the PEA group and increasing in the placebo group.
This study suggests that PEA may be a safe and potentially effective option for reducing joint pain. Future studies should investigate whether long-term supplementation leads to further improvements in pain scores.
TECHNOLOGY
INNOVATIVE ENCAPSULATION
“Micropellets in oil” capsule
-
The technology separates the active ingredients from the excipients to avoid any reactions between them during the shelf life.
-
Multi-phase hard capsule filling is a technologically interesting step. The capsule could be filled with oil and at the same time with pellets containing other active substances.
-
High bioavailability of the formulation
